Clinical trial
Safety of RAD001 in Combination With Cisplatin and Etoposide in Lung Cancer…
NCT00466466 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00466466 |
|---|---|
| Title | Safety of RAD001 in Combination With Cisplatin and Etoposide in Lung Cancer Patients |
| Official title | A Phase Ib Study Investigating the Combination of RAD001 With Cisplatin and Etoposide in Patients With Extensive-stage Small-cell Lung Cancer Not Previously Treated With Chemotherapy |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Small-Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Everolimus |
| Enrollment | 20 |
| Start date | Apr 1, 2007 |
| Primary completion | Nov 1, 2010 |
| First posted | Apr 27, 2007 |
| Last update posted | Dec 21, 2020 |
| Countries | France, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: